At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
AK002drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
In Brief
A Phase 2 clinical trial evaluating AK002 for Chronic Urticaria. Completed, enrolled 47 participants across 4 sites in 2 countries.
Detailed Summary
This is a Phase 2a, open-label study to assess the effects of AK002
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Urticaria
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionNov 2018
Study CompletionApr 2020
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartJan 23, 2018
Primary CompletionNov 21, 2018
Study CompletionApr 6, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.4 years ago
Interventions
AK002drug
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).